A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Research"
DOI: 10.1186/s12931-020-01400-5
Abstract: Background Patients with asthma uncontrolled on inhaled corticosteroids may benefit from umeclidinium (UMEC), a long-acting muscarinic antagonist. Methods This Phase IIb, double-blind study included patients with reversible, uncontrolled/partially-controlled asthma for ≥6 months, receiving ≥100 mcg/day fluticasone… read more here.
Keywords: safety; phase iib; mcg; umec mcg ... See more keywords